Rouzbeh Esfandiari

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita, Jérémie Calais, Tristan Grogan et al. · The Lancet Oncology · 2021 · 228 citations · Full text

Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?

Andrei Gafita, Hui Wang, Andrew Robertson et al. · Journal of Nuclear Medicine · 2021 · 75 citations · Full text

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Andrei Gafita, Wolfgang P. Fendler, Hui Wang et al. · European Urology · 2020 · 58 citations

Urology, Radiation Therapy, Medicine +11

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort

Jérémie Calais, Andrei Gafita, Matthias Eiber et al. · Journal of Nuclear Medicine · 2021 · 44 citations · Full text

Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)

Jérémie Calais, Johannes Czernin, Pan Thin et al. · Journal of Nuclear Medicine · 2021 · 37 citations · Full text